Cargando…

Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy

PURPOSE: We assessed prognostic factors of local control and progression-free survival (PFS) of patients treated for AJCC stages T1 and T2 cervical cancer using utero-vaginal brachytherapy after chemoradiotherapy. MATERIAL AND METHODS: This retrospective single-institution analysis included patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Faivre, Jean-Christophe, Jung, Paul, Salleron, Julia, Baumard, Florian, Courrech, Florent, Marchal, Frédéric, Peiffert, Didier, Renard, Sophie, Charra-Brunaud, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034732/
https://www.ncbi.nlm.nih.gov/pubmed/36970434
http://dx.doi.org/10.5114/jcb.2023.124936
_version_ 1784911271153369088
author Faivre, Jean-Christophe
Jung, Paul
Salleron, Julia
Baumard, Florian
Courrech, Florent
Marchal, Frédéric
Peiffert, Didier
Renard, Sophie
Charra-Brunaud, Claire
author_facet Faivre, Jean-Christophe
Jung, Paul
Salleron, Julia
Baumard, Florian
Courrech, Florent
Marchal, Frédéric
Peiffert, Didier
Renard, Sophie
Charra-Brunaud, Claire
author_sort Faivre, Jean-Christophe
collection PubMed
description PURPOSE: We assessed prognostic factors of local control and progression-free survival (PFS) of patients treated for AJCC stages T1 and T2 cervical cancer using utero-vaginal brachytherapy after chemoradiotherapy. MATERIAL AND METHODS: This retrospective single-institution analysis included patients who underwent brachytherapy after radiochemotherapy between 2005 and 2015 at the Institut de Cancérologie de Lorraine. Adjuvant hysterectomy was optional. A multivariate analysis of prognostic factors was carried out. RESULTS: Of 218 patients, 81 (37.2%) were AJCC stage T1, and 137 (62.8%) were AJCC stage T2. 167 (76.6%) patients had squamous cell carcinoma, 97 (44.5%) patients had pelvic nodal disease, and 30 (13.8%) patients had para-aortic nodal disease. One hundred eighty-four patients (84.4%) underwent concomitant chemotherapy, while adjuvant surgery was performed in 91 patients (41.9%) and 42 (46.2%) patients had pathological complete response. Median follow-up was 4.2 years, and local control was reported in 87.8% (95% CI: 83.0-91.8) and 87.2% (95% CI: 82.3-91.3) of patients at 2 and 5 years, respectively. In multivariate analysis, T stage (hazard ratio [HR] = 3.65, 95% CI: 1.27-10.46, p = 0.016) was associated with local control. PFS was reported in 67.6% (95% CI: 60.9-73.4) and 57.4% (95% CI: 49.3-64.2) of patients at 2 and 5 years, respectively. In multivariate analysis, para-aortic nodal disease (HR = 2.03, 95% CI: 1.16-3.54, p = 0.012), pathological complete response (HR = 0.33, 95% CI: 0.15-0.73, p = 0.006), and intermediate-risk clinical tumor volume of > 60 cc (HR = 1.90, 95% CI: 1.22-2.98, p = 0.005) were associated with PFS. CONCLUSIONS: Lower dose brachytherapy may benefit AJCC stages T1 and T2 tumors, whereas higher doses are required for larger tumors and para-aortic nodal disease involvement, respectively. Pathological complete response should be associated with better local control and not surgery.
format Online
Article
Text
id pubmed-10034732
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-100347322023-03-24 Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy Faivre, Jean-Christophe Jung, Paul Salleron, Julia Baumard, Florian Courrech, Florent Marchal, Frédéric Peiffert, Didier Renard, Sophie Charra-Brunaud, Claire J Contemp Brachytherapy Original Paper PURPOSE: We assessed prognostic factors of local control and progression-free survival (PFS) of patients treated for AJCC stages T1 and T2 cervical cancer using utero-vaginal brachytherapy after chemoradiotherapy. MATERIAL AND METHODS: This retrospective single-institution analysis included patients who underwent brachytherapy after radiochemotherapy between 2005 and 2015 at the Institut de Cancérologie de Lorraine. Adjuvant hysterectomy was optional. A multivariate analysis of prognostic factors was carried out. RESULTS: Of 218 patients, 81 (37.2%) were AJCC stage T1, and 137 (62.8%) were AJCC stage T2. 167 (76.6%) patients had squamous cell carcinoma, 97 (44.5%) patients had pelvic nodal disease, and 30 (13.8%) patients had para-aortic nodal disease. One hundred eighty-four patients (84.4%) underwent concomitant chemotherapy, while adjuvant surgery was performed in 91 patients (41.9%) and 42 (46.2%) patients had pathological complete response. Median follow-up was 4.2 years, and local control was reported in 87.8% (95% CI: 83.0-91.8) and 87.2% (95% CI: 82.3-91.3) of patients at 2 and 5 years, respectively. In multivariate analysis, T stage (hazard ratio [HR] = 3.65, 95% CI: 1.27-10.46, p = 0.016) was associated with local control. PFS was reported in 67.6% (95% CI: 60.9-73.4) and 57.4% (95% CI: 49.3-64.2) of patients at 2 and 5 years, respectively. In multivariate analysis, para-aortic nodal disease (HR = 2.03, 95% CI: 1.16-3.54, p = 0.012), pathological complete response (HR = 0.33, 95% CI: 0.15-0.73, p = 0.006), and intermediate-risk clinical tumor volume of > 60 cc (HR = 1.90, 95% CI: 1.22-2.98, p = 0.005) were associated with PFS. CONCLUSIONS: Lower dose brachytherapy may benefit AJCC stages T1 and T2 tumors, whereas higher doses are required for larger tumors and para-aortic nodal disease involvement, respectively. Pathological complete response should be associated with better local control and not surgery. Termedia Publishing House 2023-02-09 2023-02 /pmc/articles/PMC10034732/ /pubmed/36970434 http://dx.doi.org/10.5114/jcb.2023.124936 Text en Copyright © 2023 Termedia https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) )
spellingShingle Original Paper
Faivre, Jean-Christophe
Jung, Paul
Salleron, Julia
Baumard, Florian
Courrech, Florent
Marchal, Frédéric
Peiffert, Didier
Renard, Sophie
Charra-Brunaud, Claire
Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy
title Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy
title_full Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy
title_fullStr Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy
title_full_unstemmed Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy
title_short Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy
title_sort prognostic factors of local control and progression-free survival in ajcc stages t1 and t2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034732/
https://www.ncbi.nlm.nih.gov/pubmed/36970434
http://dx.doi.org/10.5114/jcb.2023.124936
work_keys_str_mv AT faivrejeanchristophe prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy
AT jungpaul prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy
AT salleronjulia prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy
AT baumardflorian prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy
AT courrechflorent prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy
AT marchalfrederic prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy
AT peiffertdidier prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy
AT renardsophie prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy
AT charrabrunaudclaire prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy